Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
South Korean shares hit record as chipmakers surge on OpenAI deal
2/10/2025
Miners, gold stocks power Australian shares higher ; Wall Street gains add lift
2/10/2025
Goldman Sachs' Rs 10,000 crore India portfolio : 4 stocks rally 50-155% in 1 year
2/10/2025
Tech leads Asia share rally, gold near record high on Fed rate cut bets
2/10/2025
Oil rebounds from 16-week lows on prospects of tighter Russian crude sanctions
2/10/2025
US markets regulators start shuttering as government shutdown cuts federal funding
1er/10/2025
